Catalysis Therapeutics

Catalysis Therapeutics is a preclinical-stage biotechnology company focused on developing novel small molecule therapies for muscle-wasting diseases and metabolic disorders. The company was founded in 2022 by Dr. David Glass, a renowned expert in skeletal muscle biology and former head of muscle research at Novartis and Regeneron. Catalysis leverages proprietary insights into the molecular mechanisms of muscle atrophy, specifically targeting E3 ubiquitin ligases such as MuRF1 and MAFbx. These enzymes are critical mediators of the protein degradation pathways that lead to muscle loss in aging, cancer, and other chronic conditions. By developing potent and selective inhibitors of these targets, Catalysis aims to restore muscle mass and function in patients suffering from sarcopenia and cachexia. The company is currently advancing its internal pipeline through lead optimization and early-stage discovery.